Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

1. von Minckwitz, G.
2. Puglisi, F.
3. Cortes, J.
4. Vrdoljak, E.
5. Marschner, N.
6. Zielinski, C.
7. Villanueva, C.
8. Romieu, G.
9. Lang, I.
10. Ciruelos, E.
11. De Laurentiis, M.
12. Veyret, C.
13. de Ducla, S.
14. Freudensprung, U.
15. Srock, S.
16. Gligorov, J.